Mohamed Abdulaziz Al Dawish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed Abdulaziz Al Dawish has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Asirvatham Alwin Robert
Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
17 shared publications - Ayman Abdullah Al Hayek
Research and Innovation Institute, Ministry of Defense Health Services, Riyadh, Saudi Arabia
17 shared publications Asirvatham Alwin Robert
Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
6 shared publications- Ayman A. Al Hayek
Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
3 shared publications - David C. Klonoff
Sutter Health Research Institute, Emeryville, CA, USA
3 shared publications - Wael M. Al Zahrani
Department of Endocrinology and Diabetes, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
3 shared publications
Latest Publications
- 6 April 2026
- Published by Elsevier in Primary Care Diabetes
- Vol. 20 (3) , 326-334
Long-term impact of continuous glucose monitoring on glycemic and metabolic control in type 1 diabetes: A three-year real-world evaluation
- 6 April 2026
- Published by Elsevier in Primary Care Diabetes
- Vol. 20 (3) , 326-334
Long-term impact of continuous glucose monitoring on glycemic and metabolic control in type 1 diabetes: A three-year real-world evaluation
- 20 February 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (4) , 1671-1688
Flash Glucose Monitoring System Enhances Glycemic Control and Metabolic Health in People with Type 2 Diabetes on GLP-1RA-Based Therapy: Real-World Evidence
Introduction To evaluate the effect of adding flash glucose monitoring (Flash GM) to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy on glycemic and metabolic outcomes in people with type 2 diabetes (PwT2D) who failed to achieve target HbA1c levels. Methods A prospective cohort study enrolled 264 PwT2D who were on stable GLP-1RA therapy and had failed to reach an HbA1c target of ≤ 7.0% at our institution. Participants were assigned to Flash GM + GLP-1RA or GLP-1RA alone, matched by age and baseline HbA1c using a nearest-neighbor approach, and followed for 12 months. Changes in HbA1c, body weight, lipid profile, and continuous glucose monitoring (CGM) metrics were assessed. Results After 12 months, the Flash GM group achieved a mean HbA1c reduction of − 0.58% (from 8.24 to 7.66%) versus − 0.35% (from 8.32 to 7.97%) in the GLP-1RA-only group (p < 0.001). Weight decreased by − 4.03 kg (from 83.97 to 79.95 kg) with Flash GM, significantly more than the − 2.29 kg reduction (from 84.75 to 82.50 kg) in the GLP-1RA alone group (p < 0.001). Total cholesterol and triglyceride levels decreased significantly in the Flash GM group, while HDL cholesterol levels increased, compared to minimal changes in the controls. LDL levels decreased within the Flash GM group; however, the between-group change did not reach statistical significance. Mean time-in-range was 69.6%, with low hypoglycemia exposure and no signal for increased severe events or diabetes-related emergencies. Conclusion Adding Flash GM to GLP-1RA therapy significantly improved glycemic control, weight, and lipid parameters without added risk. This supports the consideration of integrating Flash GM into routine GLP-1RA-based management to optimize outcomes in PwT2D.
- 20 February 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (4) , 1671-1688
Flash Glucose Monitoring System Enhances Glycemic Control and Metabolic Health in People with Type 2 Diabetes on GLP-1RA-Based Therapy: Real-World Evidence
Introduction To evaluate the effect of adding flash glucose monitoring (Flash GM) to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy on glycemic and metabolic outcomes in people with type 2 diabetes (PwT2D) who failed to achieve target HbA1c levels. Methods A prospective cohort study enrolled 264 PwT2D who were on stable GLP-1RA therapy and had failed to reach an HbA1c target of ≤ 7.0% at our institution. Participants were assigned to Flash GM + GLP-1RA or GLP-1RA alone, matched by age and baseline HbA1c using a nearest-neighbor approach, and followed for 12 months. Changes in HbA1c, body weight, lipid profile, and continuous glucose monitoring (CGM) metrics were assessed. Results After 12 months, the Flash GM group achieved a mean HbA1c reduction of − 0.58% (from 8.24 to 7.66%) versus − 0.35% (from 8.32 to 7.97%) in the GLP-1RA-only group (p < 0.001). Weight decreased by − 4.03 kg (from 83.97 to 79.95 kg) with Flash GM, significantly more than the − 2.29 kg reduction (from 84.75 to 82.50 kg) in the GLP-1RA alone group (p < 0.001). Total cholesterol and triglyceride levels decreased significantly in the Flash GM group, while HDL cholesterol levels increased, compared to minimal changes in the controls. LDL levels decreased within the Flash GM group; however, the between-group change did not reach statistical significance. Mean time-in-range was 69.6%, with low hypoglycemia exposure and no signal for increased severe events or diabetes-related emergencies. Conclusion Adding Flash GM to GLP-1RA therapy significantly improved glycemic control, weight, and lipid parameters without added risk. This supports the consideration of integrating Flash GM into routine GLP-1RA-based management to optimize outcomes in PwT2D.
- 6 August 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (10) , 4977-4992
Evaluation of Glycemia Risk Index and Continuous Glucose Monitoring Outcomes Following the Transition to an Advanced Hybrid Closed-Loop System in Type 1 Diabetes
Introduction Advanced hybrid closed-loop (AHCL) systems have shown promise in improving glycemic control in adults with type 1 diabetes (T1D), yet real-world evidence remains limited. This study evaluated the impact of transitioning from multiple daily injections (MDI) or conventional continuous subcutaneous insulin infusion (CSII) to the Tandem t:slim X2™ Control-IQ® AHCL system on glycemic outcomes in adults with T1D. Methods In this retrospective study, 56 non-pregnant adults with T1D were followed for 6 months. Primary outcomes were changes in the Glycemia Risk Index (GRI) and percentage time in the tight range (%TiTR70-140). Secondary outcomes included other standardized ambulatory glucose profile metrics as well as additional glycemic, anthropometric, and insulin dosing measures. Results Transition to the Control-IQ system increased %TiTR70-140 by 11.5 percentage points and reduced GRI by 23.5 points. Both components of the GRI, hypoglycemia risk (%Chypo) and hyperglycemia risk (%Chyper), improved significantly. Hemoglobin A1c decreased by 1.0%, time in range (%TIR70-180) improved by 13.6 percentage points, and glycemic variability (CV%) showed marked improvement. Total daily insulin dose decreased by 34%, accompanied by modest weight loss. No diabetic ketoacidosis episodes were reported throughout the study period. Conclusion Transitioning to the Tandem t:slim X2 Control-IQ AHCL system led to significant improvements in tight glycemic control, glycemic risk reduction, and insulin efficiency, with a favorable safety profile. These findings support broader adoption of AHCL technology and underscore the need for prospective multicenter studies.
- 6 August 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (10) , 4977-4992
Evaluation of Glycemia Risk Index and Continuous Glucose Monitoring Outcomes Following the Transition to an Advanced Hybrid Closed-Loop System in Type 1 Diabetes
Introduction Advanced hybrid closed-loop (AHCL) systems have shown promise in improving glycemic control in adults with type 1 diabetes (T1D), yet real-world evidence remains limited. This study evaluated the impact of transitioning from multiple daily injections (MDI) or conventional continuous subcutaneous insulin infusion (CSII) to the Tandem t:slim X2™ Control-IQ® AHCL system on glycemic outcomes in adults with T1D. Methods In this retrospective study, 56 non-pregnant adults with T1D were followed for 6 months. Primary outcomes were changes in the Glycemia Risk Index (GRI) and percentage time in the tight range (%TiTR70-140). Secondary outcomes included other standardized ambulatory glucose profile metrics as well as additional glycemic, anthropometric, and insulin dosing measures. Results Transition to the Control-IQ system increased %TiTR70-140 by 11.5 percentage points and reduced GRI by 23.5 points. Both components of the GRI, hypoglycemia risk (%Chypo) and hyperglycemia risk (%Chyper), improved significantly. Hemoglobin A1c decreased by 1.0%, time in range (%TIR70-180) improved by 13.6 percentage points, and glycemic variability (CV%) showed marked improvement. Total daily insulin dose decreased by 34%, accompanied by modest weight loss. No diabetic ketoacidosis episodes were reported throughout the study period. Conclusion Transitioning to the Tandem t:slim X2 Control-IQ AHCL system led to significant improvements in tight glycemic control, glycemic risk reduction, and insulin efficiency, with a favorable safety profile. These findings support broader adoption of AHCL technology and underscore the need for prospective multicenter studies.
- Open Access
- 31 May 2025
- Published by Wolters Kluwer Health in Journal of Family Medicine and Primary Care
- Vol. 14 (5) , 1889-1895
Exploring the clinical features and complications of type 1 diabetes mellitus in Saudi Arabia: A retrospective analysis
Background and Aim: On a global scale Type 1 diabetes (T1D) ranks high on the list of most prevalent endocrine metabolic disorders; it affects children and adolescents. Frequently, T1D causes complications that can be serious, acute and chronic. This present study aims to investigate the clinical features and complications associated with T1D in Saudi Arabia. Methods: In this retrospective cohort study, individuals with T1D were investigated at the Diabetes Treatment Center, Prince Sultan Military Medical City (PSMMC) in Riyadh, Saudi Arabia, focusing on patients aged 14 to 60 years. Data were collected on each patient, regarding demographic information (gender, age) and diabetes-related criteria (duration of diabetes, age when diagnosed, current and initial HbA1c values, and treatment modalities). Accurate documentation was done of the disease-related complications such as hypertension, dyslipidemia, and a plethora of diabetic retinopathy (whether non-proliferative, proliferative, or macular edema), plus nephropathy/end-stage renal disease, neuropathy, coronary artery disease, peripheral vascular disease, and cerebrovascular disease. Results: The patient cohort comprises 46.1% males and 53.9% females. Different groups revealed similar biochemical markers, like HbA1c and creatinine clearance. Patients with diabetes for a longer duration had a higher probability of statin intake (P = 0.0001) and GLP-1 therapy (P = 0.004). A striking rise was evident in microalbuminuria and retinopathy, some disease-related complications, with the duration of diabetes. While a few of the complications show higher frequency in patients having HbA1c >7.5%, several differences are noted, although not statistically significant; this is indicative of the complexities in the relationships between diabetes management and the final results. Conclusion: In summary, younger patients with a more contracted timespan of diabetes will experience fewer complications than those with a lengthier duration of the disease, who in reality will face higher risks. Therefore, to achieve improved health outcomes, diabetes patients require effective treatment management.
- 31 May 2025
- Published by Wolters Kluwer Health in Journal of Family Medicine and Primary Care
- Vol. 14 (5) , 1889-1895
Open AccessExploring the clinical features and complications of type 1 diabetes mellitus in Saudi Arabia: A retrospective analysis
Background and Aim: On a global scale Type 1 diabetes (T1D) ranks high on the list of most prevalent endocrine metabolic disorders; it affects children and adolescents. Frequently, T1D causes complications that can be serious, acute and chronic. This present study aims to investigate the clinical features and complications associated with T1D in Saudi Arabia. Methods: In this retrospective cohort study, individuals with T1D were investigated at the Diabetes Treatment Center, Prince Sultan Military Medical City (PSMMC) in Riyadh, Saudi Arabia, focusing on patients aged 14 to 60 years. Data were collected on each patient, regarding demographic information (gender, age) and diabetes-related criteria (duration of diabetes, age when diagnosed, current and initial HbA1c values, and treatment modalities). Accurate documentation was done of the disease-related complications such as hypertension, dyslipidemia, and a plethora of diabetic retinopathy (whether non-proliferative, proliferative, or macular edema), plus nephropathy/end-stage renal disease, neuropathy, coronary artery disease, peripheral vascular disease, and cerebrovascular disease. Results: The patient cohort comprises 46.1% males and 53.9% females. Different groups revealed similar biochemical markers, like HbA1c and creatinine clearance. Patients with diabetes for a longer duration had a higher probability of statin intake (P = 0.0001) and GLP-1 therapy (P = 0.004). A striking rise was evident in microalbuminuria and retinopathy, some disease-related complications, with the duration of diabetes. While a few of the complications show higher frequency in patients having HbA1c >7.5%, several differences are noted, although not statistically significant; this is indicative of the complexities in the relationships between diabetes management and the final results. Conclusion: In summary, younger patients with a more contracted timespan of diabetes will experience fewer complications than those with a lengthier duration of the disease, who in reality will face higher risks. Therefore, to achieve improved health outcomes, diabetes patients require effective treatment management.
- 1 February 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (1) , 59
Evaluation of glycemia risk index and continuous glucose monitoring-derived metrics in type 1 diabetes: a real-world observational study
Objectives The Glycemia Risk Index (GRI) quantifies the risk of glycemic events by considering both hypoglycemic and hyperglycemic episodes, offering a comprehensive evaluation of glycemia. While associations between GRI and various glycometric indicators have been established in clinical trials using continuous glucose monitoring (CGM), real-world assessments, particularly with intermittent scanning CGM (isCGM), are underexplored. This study examines these associations and their clinical implications in individuals with Type 1 Diabetes (T1D). Methods We conducted a retrospective study involving individuals with T1D undergoing intensive insulin therapy. All participants had used isCGM for at least three months. We collected clinical, metabolic, and glycemic data and calculated the GRI, with its components for hypoglycemia (CHypo) and hyperglycemia (CHyper). We then assessed the correlation between the GRI and traditional glycemic metrics in relation to the coefficient of variation (CV). Results The study included 194 patients (105 males, 89 females) with a median age of 21.5 years for adults and 16 years for adolescents. Of these, 62.4% were on multiple daily injections, and 37.6% used insulin pumps. GRI showed a significant negative correlation with Time in Range (%TIR70 − 180) (p < 0.001) and a positive association with various glycemic measures such as glycemic variability (r = 0.33, p < 0.001). Individuals with lower glycemic variability (CV< 36%) had significantly higher %TIR70 − 180 (63% vs. 39%, p < 0.01) and lower GRI (40 vs. 45.8, p < 0.01), CHyper (20 vs. 24, p = 0.01), and CHypo (2.6 vs. 3.4, p < 0.01). Conclusions GRI correlates with key glycemic metrics, indicating its potential utility in comprehensive glycemia assessment. These findings highlight the importance of individualized treatment approaches and suggest GRI’s clinical relevance in optimizing glycemic management strategies for individuals with T1D.
- 1 February 2025
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (1) , 59
Evaluation of glycemia risk index and continuous glucose monitoring-derived metrics in type 1 diabetes: a real-world observational study
Objectives The Glycemia Risk Index (GRI) quantifies the risk of glycemic events by considering both hypoglycemic and hyperglycemic episodes, offering a comprehensive evaluation of glycemia. While associations between GRI and various glycometric indicators have been established in clinical trials using continuous glucose monitoring (CGM), real-world assessments, particularly with intermittent scanning CGM (isCGM), are underexplored. This study examines these associations and their clinical implications in individuals with Type 1 Diabetes (T1D). Methods We conducted a retrospective study involving individuals with T1D undergoing intensive insulin therapy. All participants had used isCGM for at least three months. We collected clinical, metabolic, and glycemic data and calculated the GRI, with its components for hypoglycemia (CHypo) and hyperglycemia (CHyper). We then assessed the correlation between the GRI and traditional glycemic metrics in relation to the coefficient of variation (CV). Results The study included 194 patients (105 males, 89 females) with a median age of 21.5 years for adults and 16 years for adolescents. Of these, 62.4% were on multiple daily injections, and 37.6% used insulin pumps. GRI showed a significant negative correlation with Time in Range (%TIR70 − 180) (p < 0.001) and a positive association with various glycemic measures such as glycemic variability (r = 0.33, p < 0.001). Individuals with lower glycemic variability (CV< 36%) had significantly higher %TIR70 − 180 (63% vs. 39%, p < 0.01) and lower GRI (40 vs. 45.8, p < 0.01), CHyper (20 vs. 24, p = 0.01), and CHypo (2.6 vs. 3.4, p < 0.01). Conclusions GRI correlates with key glycemic metrics, indicating its potential utility in comprehensive glycemia assessment. These findings highlight the importance of individualized treatment approaches and suggest GRI’s clinical relevance in optimizing glycemic management strategies for individuals with T1D.
- Open Access
- 28 September 2023
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 15 (1) , 1-8
Metabolic control, adherence to the gluten-free diet and quality of life among patients with type 1 diabetes and celiac disease
Aims: In this cross-sectional study, we aimed to evaluate metabolic control, adherence to a gluten-free diet (GFD), and quality of life (QoL) in individuals with type 1 diabetes (T1D) and celiac disease (CD). Methods: We targeted individuals with T1D and CD at a major tertiary hospital in Saudi Arabia. We gathered retrospective data from medical records and prospectively assessed glycemic control using HbA1c and ambulatory glucose metrics, adherence to a GFD using the Celiac Dietary Adherence Test (CDAT), and QoL using the Celiac Disease Quality of Life survey (CD-QoL). Results: Forty-eight out of 1095 patients screened (4.38%) were included. Mean age and HbA1c were 21.3 (± 6.6) and 8.3% (± 0.8%). The average time in range% and above range% were 38.5 (range 24–68) and 29.6 (± 7.4). The median hypoglycemic events/month was 8, with a median duration of 80 min. The median overall CDAT and CD-QoL scores were 20.5 and 54. No significant correlations were observed between glucose management indicator (GMI), % in target, and CDAT/CD-QoL scores (all p > 0.05). Conclusions: No significant effect of GFD on QoL or glycemic control was observed. Further prospective studies are warranted to establish solid evidence of the impact of GFD on individuals with T1D and CD.
- 28 September 2023
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 15 (1) , 1-8
Open AccessMetabolic control, adherence to the gluten-free diet and quality of life among patients with type 1 diabetes and celiac disease
Aims: In this cross-sectional study, we aimed to evaluate metabolic control, adherence to a gluten-free diet (GFD), and quality of life (QoL) in individuals with type 1 diabetes (T1D) and celiac disease (CD). Methods: We targeted individuals with T1D and CD at a major tertiary hospital in Saudi Arabia. We gathered retrospective data from medical records and prospectively assessed glycemic control using HbA1c and ambulatory glucose metrics, adherence to a GFD using the Celiac Dietary Adherence Test (CDAT), and QoL using the Celiac Disease Quality of Life survey (CD-QoL). Results: Forty-eight out of 1095 patients screened (4.38%) were included. Mean age and HbA1c were 21.3 (± 6.6) and 8.3% (± 0.8%). The average time in range% and above range% were 38.5 (range 24–68) and 29.6 (± 7.4). The median hypoglycemic events/month was 8, with a median duration of 80 min. The median overall CDAT and CD-QoL scores were 20.5 and 54. No significant correlations were observed between glucose management indicator (GMI), % in target, and CDAT/CD-QoL scores (all p > 0.05). Conclusions: No significant effect of GFD on QoL or glycemic control was observed. Further prospective studies are warranted to establish solid evidence of the impact of GFD on individuals with T1D and CD.
- 1 July 2023
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 19 (6) , 1
Anxiety, Depression, and Fear among People with and without Diabetes During the Transmission of SARS-CoV-2 Omicron Variant
Background and Aim: The present study aimed to evaluate the anxiety, depression, and fear in people with and without diabetes during the transmission of the SARS-CoV-2 Omicron variant. Methods: In this comparative study (n= 353), people with diabetes (n= 121) and those without diabetes (n= 232) were investigated for physiological aspects of COVID-19 during the SARS-CoV-2 Omicron variant outbreak. This study was performed at the Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia. On request, the participants responded to the survey questionnaires, providing data on demographics, Generalized Anxiety Disorder (GAD-7), and Patient Health Questionnaire-2 (PHQ-2) to screen for anxiety, depression, and COVID-19-related fears. Results: The GAD statement revealed a significantly higher degree of nervousness and anxiety among people with diabetes when compared to people without diabetes (P = 0.001). For the other GAD statements, no statistical difference was observed between the responses of people with and without diabetes, including the overall GAD-7 (P = 0.091). The PHQ-2 statement, concerning a feeling of depression or hopelessness noted a significant escalation among diabetes compared to nondiabetes (P = 0.004). Furthermore, in the overall PHQ-2, a significant escalation (P = 0.011) was noticed among people with diabetes compared to nondiabetes. In addition, people with diabetes had a significantly high (P = 0.037) COVID-19-related fear reported, compared to people without diabetes. Conclusion: The need for comprehensive research is urgent, as it will facilitate a better understanding of the physiological aspects of COVID-19 for patients with diabetes.
- 1 July 2023
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 19 (6) , 1
Anxiety, Depression, and Fear among People with and without Diabetes During the Transmission of SARS-CoV-2 Omicron Variant
Background and Aim: The present study aimed to evaluate the anxiety, depression, and fear in people with and without diabetes during the transmission of the SARS-CoV-2 Omicron variant. Methods: In this comparative study (n= 353), people with diabetes (n= 121) and those without diabetes (n= 232) were investigated for physiological aspects of COVID-19 during the SARS-CoV-2 Omicron variant outbreak. This study was performed at the Prince Sultan Military Medical City (PSMMC), Riyadh, Saudi Arabia. On request, the participants responded to the survey questionnaires, providing data on demographics, Generalized Anxiety Disorder (GAD-7), and Patient Health Questionnaire-2 (PHQ-2) to screen for anxiety, depression, and COVID-19-related fears. Results: The GAD statement revealed a significantly higher degree of nervousness and anxiety among people with diabetes when compared to people without diabetes (P = 0.001). For the other GAD statements, no statistical difference was observed between the responses of people with and without diabetes, including the overall GAD-7 (P = 0.091). The PHQ-2 statement, concerning a feeling of depression or hopelessness noted a significant escalation among diabetes compared to nondiabetes (P = 0.004). Furthermore, in the overall PHQ-2, a significant escalation (P = 0.011) was noticed among people with diabetes compared to nondiabetes. In addition, people with diabetes had a significantly high (P = 0.037) COVID-19-related fear reported, compared to people without diabetes. Conclusion: The need for comprehensive research is urgent, as it will facilitate a better understanding of the physiological aspects of COVID-19 for patients with diabetes.
- Open Access
- 5 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e33416
Comparison of Point-of-Care and Laboratory Glycated Hemoglobin A1c and Its Relationship to Time-in-Range and Glucose Variability: A Real-World Study
The main objective of the current study was to perform a comparison of point-of-care testing for hemoglobin A1c (POCT-HbA1c) versus the standard laboratory method (Lab HbA1c) and their relationship to time-in-range (TIR) and glucose variability (GV) among patients with diabetes mellitus (DM) presented to the outpatient diabetes clinics. This single-center cross-sectional study was carried out on diabetic patients (aged ≥14 years of both genders) who undergo routine follow-up at our institution and whose physicians ordered HbA1c analysis for routine care. The included patients were those using the intermittently scanned continuous glucose monitoring (isCGM) Abbott’s FreeStyle Libre system for at least three months and regular CGM users with at least 70% use. We included 97 diabetic patients (41 female and 56 male), with a median age of 25 years (Interquartile range= 18) and a mean DM duration of 10.33±5.48 years. The mean values of Lab-HbA1c and POCT HbA1c were 8.82%±0.85% and 8.53%±0.89%, respectively. The TIR, time below range, and time above range were 33.47±14.38 minutes (47.78%±14.32%), 5.44±2.58 minutes (8.41%±4.42%), and 28.8±8.27 minutes (43.81%±13.22%), respectively. According to the Bland-Altman plot analysis, the POCT-HbA1c values are consistent with the standard Lab-HbA1c values (SD of bias= 0.55, and 95% CI= -0.78 to 1.4). The univariate linear regression analysis showed a statistically significant relationship between laboratory HbA1c and POCT HbA1c (R2= 0.637, p p p= 0.032). After adjusting for age, gender, disease duration, diabetes type, and percentage of sensor data in a multivariable linear regression model, the linear associations remained significant (all p < 0.05). The current findings show that TIR and GV can be used as endpoints and valuable parameters for the therapy of DM.
- 5 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e33416
Open AccessComparison of Point-of-Care and Laboratory Glycated Hemoglobin A1c and Its Relationship to Time-in-Range and Glucose Variability: A Real-World Study
The main objective of the current study was to perform a comparison of point-of-care testing for hemoglobin A1c (POCT-HbA1c) versus the standard laboratory method (Lab HbA1c) and their relationship to time-in-range (TIR) and glucose variability (GV) among patients with diabetes mellitus (DM) presented to the outpatient diabetes clinics. This single-center cross-sectional study was carried out on diabetic patients (aged ≥14 years of both genders) who undergo routine follow-up at our institution and whose physicians ordered HbA1c analysis for routine care. The included patients were those using the intermittently scanned continuous glucose monitoring (isCGM) Abbott’s FreeStyle Libre system for at least three months and regular CGM users with at least 70% use. We included 97 diabetic patients (41 female and 56 male), with a median age of 25 years (Interquartile range= 18) and a mean DM duration of 10.33±5.48 years. The mean values of Lab-HbA1c and POCT HbA1c were 8.82%±0.85% and 8.53%±0.89%, respectively. The TIR, time below range, and time above range were 33.47±14.38 minutes (47.78%±14.32%), 5.44±2.58 minutes (8.41%±4.42%), and 28.8±8.27 minutes (43.81%±13.22%), respectively. According to the Bland-Altman plot analysis, the POCT-HbA1c values are consistent with the standard Lab-HbA1c values (SD of bias= 0.55, and 95% CI= -0.78 to 1.4). The univariate linear regression analysis showed a statistically significant relationship between laboratory HbA1c and POCT HbA1c (R2= 0.637, p p p= 0.032). After adjusting for age, gender, disease duration, diabetes type, and percentage of sensor data in a multivariable linear regression model, the linear associations remained significant (all p < 0.05). The current findings show that TIR and GV can be used as endpoints and valuable parameters for the therapy of DM.